医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Ultivue Announces $50M Financing Round

2021年04月27日 PM11:07
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, Mass.

Ultivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&E for tissue phenotyping, today announced the completion of a $50 million Series D round of financing. New investors include Ally Bridge Group, Pura Vida Investments and Tao Capital Partners. Previous venture investors in Ultivue who also participated in the financing include ARCH Ventures, Northpond Ventures and Applied Ventures, LLC.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005387/en/

Multiplexed immunofluorescence image depicting immune infiltrates in a non-small cell lung cancer (NSCLC) sample. (Photo: Business Wire)

Multiplexed immunofluorescence image depicting immune infiltrates in a non-small cell lung cancer (NSCLC) sample. (Photo: Business Wire)

This additional funding will help Ultivue strengthen its position in the market, deliver innovative solutions to address the dynamic nature of tumor biology from precious tissue samples and to provide researchers and pathologists with the ability to fully realize the potential of tissue biomarkers within digital pathology workflows.

Anna Yaeger, President and Portfolio Manager commented, “Ally Bridge Group is excited to be long term partners with Ultivue. We believe the company’s differentiated kit-based approach to multiplex immunofluorescence is well positioned to capitalize on the spatial biology revolution and creates maximum flexibility to support academic, biopharma, and CRO customers.”

“What Ultivue has is remarkably capable. They provide fast, accurate, previously unattainable multiplexed protein marker information at high resolution and on existing hardware. It is going to be exciting to see a well-resourced, well led Ultivue offer great capabilities to the biotech and pharma oncology community,” said Keith Crandell, Co-founder & Managing Director from ARCH Ventures.

“Ultivue is driving to make immunotherapy a reality for every patient that needs it with leading technology that enables advanced exploration and interrogation of tissue samples for precision medicine research. We’re proud to continue supporting the Ultivue team,” said Adam Wieschhaus, Ph.D., CFA, Director at Northpond Ventures.

“We’re excited to welcome our newest investors, and greatly appreciate the support from our existing investment partners,” says Jacques Corriveau, President and CEO of Ultivue. “This funding will allow us to expand our commercial efforts while also increasing the scope of our research and development in order to remain at the forefront of innovation and provide biological insights for our customers as they work to address the challenge of therapeutic response rates in patients using immunotherapy.”

About Ultivue:

Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005387/en/

CONTACT

Mark Rees

Ultivue

mark.rees@ultivue.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
  • Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
  • DKT International Implements Traditional and New Forms of Marketing in Africa, South America, and Southeast Asia to Expand Access to Contraceptives
  • オルガノンが計画外妊娠をめぐり世界規模の対話の喚起を目指す
  • IHMA Opens Microbiology Reference Laboratory in Shanghai, China to Further Support Global Anti-Infective Product Discovery and Development